{"id":"placebo-for-dapagliflozin","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL429910","moleculeType":"Small molecule","molecularWeight":"408.88"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. It relies on the placebo effect—psychological and physiological responses to the expectation of treatment—rather than any direct molecular mechanism. In the context of dapagliflozin trials, placebo serves as the comparator arm to demonstrate that observed benefits are due to the active SGLT2 inhibitor, not expectation alone.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:45.634Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Used as control comparator in clinical trials for dapagliflozin efficacy evaluation"}]},"trialDetails":[{"nctId":"NCT06742723","phase":"PHASE3","title":"A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-03","conditions":"Chronic Kidney Disease and Hypertension","enrollment":5000},{"nctId":"NCT07488689","phase":"PHASE3","title":"Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-07","conditions":"Septic Shock","enrollment":568},{"nctId":"NCT06307652","phase":"PHASE3","title":"Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-04-12","conditions":"Heart Failure and Impaired Kidney Function","enrollment":4800},{"nctId":"NCT06364930","phase":"PHASE4","title":"SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2024-03-26","conditions":"Chronic Hepatitis B","enrollment":412},{"nctId":"NCT07273838","phase":"PHASE2","title":"Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome","status":"RECRUITING","sponsor":"Yale University","startDate":"2026-03-05","conditions":"Heart Failure, Acute Kidney Injury","enrollment":130},{"nctId":"NCT07018622","phase":"PHASE2","title":"Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity","status":"RECRUITING","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2025-05-07","conditions":"Solid Tumors, Cisplatin Nephrotoxicity","enrollment":46},{"nctId":"NCT06785116","phase":"PHASE4","title":"A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2025-03-02","conditions":"Gestational Hypertension, Hypertension in Pregnancy, Pre-Eclampsia","enrollment":200},{"nctId":"NCT07280585","phase":"PHASE3","title":"STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease","status":"RECRUITING","sponsor":"University of Cologne","startDate":"2025-12-16","conditions":"Polycystic Kidney, Autosomal Dominant","enrollment":420},{"nctId":"NCT07025629","phase":"PHASE3","title":"Dapagliflozin for Cardio-renal Protection After ICU Discharge","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-12-02","conditions":"Heart Failure and Chronic Kidney Disease Post-ICU","enrollment":600},{"nctId":"NCT06907251","phase":"PHASE3","title":"Dapagliflozin for Long COVID Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2026-04-01","conditions":"COVID - 19, Long COVID Syndrome, SARS CoV-2","enrollment":192},{"nctId":"NCT06677060","phase":"PHASE3","title":"Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-14","conditions":"Heart Failure","enrollment":11300},{"nctId":"NCT05139914","phase":"PHASE4","title":"Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"Boston University","startDate":"2022-05-31","conditions":"Diabetes Mellitus, Type 2, Endothelial Dysfunction","enrollment":4},{"nctId":"NCT07323524","phase":"PHASE4","title":"Dapagliflozin in Active Lupus Nephritis","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-02-01","conditions":"Lupus Nephritis (LN)","enrollment":33},{"nctId":"NCT04930549","phase":"PHASE2","title":"Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC)","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2022-10-18","conditions":"Renal Insufficiency, Chronic","enrollment":32},{"nctId":"NCT07391267","phase":"NA","title":"Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-02-01","conditions":"Chronic Kidney Diseases, MAFLD","enrollment":90},{"nctId":"NCT06268873","phase":"PHASE3","title":"A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-03-29","conditions":"Chronic Kidney Disease and Hypertension","enrollment":2554},{"nctId":"NCT06263673","phase":"PHASE4","title":"Anti-Diabetic Medications to Fight PD and LBD","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2024-05-07","conditions":"Lewy Body Dementia, Parkinson Disease","enrollment":18},{"nctId":"NCT05179356","phase":"PHASE2","title":"Dapagliflozin in Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Mads Ersbøll","startDate":"2023-01-01","conditions":"Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension","enrollment":52},{"nctId":"NCT06269484","phase":"PHASE2","title":"A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-02-15","conditions":"Liver Cirrhosis","enrollment":73},{"nctId":"NCT07344922","phase":"PHASE3","title":"SGLT2 Inhibitors in Non-Diabetic CKD: Effects on Vascular Calcification and Anemia","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2022-09-01","conditions":"Chronic Kidney Disease, Anemia, Cardiovascular Calcification","enrollment":100},{"nctId":"NCT05764057","phase":"PHASE3","title":"DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-06-12","conditions":"AMI, STEMI, NSTEMI","enrollment":450},{"nctId":"NCT07174687","phase":"PHASE2","title":"SGLT2 Inhibitors in Geographic Atrophy","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-12-02","conditions":"Retinal Degeneration, Retinal Diseases, Eye Diseases","enrollment":70},{"nctId":"NCT06560333","phase":"PHASE3","title":"iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD)","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-11-30","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT06317051","phase":"PHASE3","title":"Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kirby Institute","startDate":"2024-12-16","conditions":"HIV Infections, Weight Gain","enrollment":300},{"nctId":"NCT05374291","phase":"PHASE3","title":"The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD","status":"ENROLLING_BY_INVITATION","sponsor":"University Medical Center Groningen","startDate":"2022-11-08","conditions":"Kidney Disease, Chronic, Renal Transplant Failure, Heart Failure","enrollment":1750},{"nctId":"NCT07239011","phase":"PHASE1, PHASE2","title":"Dapagliflozin in Depression","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-11-01","conditions":"Depression","enrollment":60},{"nctId":"NCT07245069","phase":"PHASE2","title":"Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients","status":"RECRUITING","sponsor":"University Medical Centre Ljubljana","startDate":"2025-02-01","conditions":"Heart Failure, Anthracycline-induced Cardiac Toxicity, Endothelial Function (FMD)","enrollment":100},{"nctId":"NCT07056699","phase":"PHASE3","title":"SGLT2i, Pioglitazone, and Ketone Production in T1D","status":"NOT_YET_RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2026-01-30","conditions":"Type1diabetes","enrollment":24},{"nctId":"NCT06762964","phase":"PHASE2","title":"CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-05-16","conditions":"Fontan Circulation, Single Ventricle Heart Disease, HFpEF - Heart Failure With Preserved Ejection Fraction","enrollment":27},{"nctId":"NCT06888505","phase":"PHASE2","title":"Dapagliflozin to Prevent Anthracycline-Induced Cardiotoxicity","status":"COMPLETED","sponsor":"Hawler Medical University","startDate":"2024-09-01","conditions":"Anthracyclines-Induced Cardiotoxicity, Cardiotoxicity","enrollment":90},{"nctId":"NCT05468203","phase":"PHASE3","title":"PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care","status":"RECRUITING","sponsor":"The George Institute","startDate":"2023-11-29","conditions":"Acute Kidney Injury","enrollment":3000},{"nctId":"NCT06647745","phase":"PHASE3","title":"A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension","status":"RECRUITING","sponsor":"THPharm Corp.","startDate":"2025-04-10","conditions":"Type 2 Diabetes, Hypertension","enrollment":221},{"nctId":"NCT05516498","phase":"PHASE2","title":"Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2022-10-31","conditions":"Liver Cirrhosis","enrollment":205},{"nctId":"NCT06054035","phase":"PHASE4","title":"SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2023-10-26","conditions":"Type2diabetes, PreDiabetes, Renal Failure","enrollment":170},{"nctId":"NCT07070765","phase":"NA","title":"Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity","status":"NOT_YET_RECRUITING","sponsor":"University of Aberdeen","startDate":"2025-11-01","conditions":"Breast Cancer","enrollment":70},{"nctId":"NCT01439854","phase":"NA","title":"Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2011-03","conditions":"Insulin Sensitivity, Multiple Mitochondrial Dysfunctions Syndrome","enrollment":18},{"nctId":"NCT04363697","phase":"PHASE4","title":"Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)","status":"COMPLETED","sponsor":"The TIMI Study Group","startDate":"2020-09-24","conditions":"Acute Heart Failure, Heart Failure","enrollment":2401},{"nctId":"NCT03919656","phase":"PHASE4","title":"SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","startDate":"2019-05-12","conditions":"Type 2 Diabetes Mellitus","enrollment":60},{"nctId":"NCT07020377","phase":"PHASE1, PHASE2","title":"Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amira Bisher,PhD","startDate":"2024-01-15","conditions":"Diabetes Mellitus, Non Alcholic Fatty Liver Disease","enrollment":60},{"nctId":"NCT05590143","phase":"PHASE4","title":"proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amsterdam UMC","startDate":"2023-06-09","conditions":"Acute Kidney Injury, Cardiac Surgery, Sodium-Glucose Transporter 2 Inhibitor","enrollment":784},{"nctId":"NCT06350123","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-05-01","conditions":"Chronic Kidney Disease","enrollment":324},{"nctId":"NCT05570305","phase":"PHASE2","title":"Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2022-10-06","conditions":"Chronic Kidney Diseases","enrollment":42},{"nctId":"NCT06750458","phase":"PHASE3","title":"Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor Patients","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2025-08-20","conditions":"Glioma, Dapagliflozin (Forxiga), Dexamethasone","enrollment":75},{"nctId":"NCT05748925","phase":"PHASE4","title":"Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2022-10-01","conditions":"SLE, Lupus Nephritis, SGLT2 Inhibitors","enrollment":84},{"nctId":"NCT05852704","phase":"PHASE3","title":"SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF","status":"RECRUITING","sponsor":"Region Örebro County","startDate":"2024-04-04","conditions":"Chronic Coronary Syndrome, Atrial Fibrillation","enrollment":800},{"nctId":"NCT03899402","phase":"PHASE2, PHASE3","title":"Triple Therapy in T1DM","status":"ACTIVE_NOT_RECRUITING","sponsor":"State University of New York at Buffalo","startDate":"2019-05-01","conditions":"Type 1 Diabetes Mellitus","enrollment":78},{"nctId":"NCT06000462","phase":"PHASE4","title":"The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oman Ministry of Health","startDate":"2024-04-22","conditions":"Obesity, Dapagliflozin Adverse Reaction, Weight Loss","enrollment":150},{"nctId":"NCT04965935","phase":"PHASE3","title":"Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2021-07-15","conditions":"Kidney Transplant Recipients, Post-transplant Diabetes Mellitus, Type 2 Diabetes","enrollment":52},{"nctId":"NCT04564742","phase":"PHASE3","title":"Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-12-22","conditions":"Acute Myocardial Infarction, Heart Failure","enrollment":4017},{"nctId":"NCT05795400","phase":"NA","title":"Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","startDate":"2022-06-01","conditions":"Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction","enrollment":50},{"nctId":"NCT06615674","phase":"PHASE4","title":"Effect of Dapagliflozin Administration on the Apoptosis Levels of Patients With Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Yoga Yudhistira","startDate":"2024-09-21","conditions":"Acute Myocardial Infarction (AMI), STEMI - ST Elevation Myocardial Infarction (MI), NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)","enrollment":40},{"nctId":"NCT06820567","phase":"PHASE3","title":"Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients with Type 2 Diabetes and CKD","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-03-01","conditions":"Chronic Kidney Diseases, Diabetes Type 2","enrollment":210},{"nctId":"NCT05459701","phase":"PHASE4","title":"Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)","status":"COMPLETED","sponsor":"Rehab Werida","startDate":"2022-05-01","conditions":"Nonalcoholic Fatty Liver Disease, Type 2 Diabetes","enrollment":50},{"nctId":"NCT05345327","phase":"PHASE3","title":"SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes","status":"RECRUITING","sponsor":"The George Institute","startDate":"2023-01-01","conditions":"Type 2 Diabetes","enrollment":994},{"nctId":"NCT04492722","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2020-10-01","conditions":"Chronic Kidney Disease","enrollment":613},{"nctId":"NCT04234867","phase":"PHASE1","title":"Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D)","status":"TERMINATED","sponsor":"Kinderkrankenhaus auf der Bult","startDate":"2022-05-18","conditions":"Type 1 Diabetes, Diabetic Ketoacidosis","enrollment":2},{"nctId":"NCT06304857","phase":"PHASE3","title":"CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL","status":"RECRUITING","sponsor":"4th Military Clinical Hospital with Polyclinic, Poland","startDate":"2024-04-15","conditions":"Breast Cancer, Heart Failure","enrollment":188},{"nctId":"NCT04792190","phase":"PHASE4","title":"Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2021-07-27","conditions":"Atrial Fibrillation","enrollment":25},{"nctId":"NCT06711185","phase":"PHASE3","title":"Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy","status":"RECRUITING","sponsor":"University of Campinas, Brazil","startDate":"2024-01-30","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT04869124","phase":"PHASE4","title":"Dapagliflozin on Volume Vascular Outcomes.","status":"COMPLETED","sponsor":"Frank Ruschitzka","startDate":"2021-02-15","conditions":"Heart Failure，Congestive","enrollment":80},{"nctId":"NCT05735197","phase":"PHASE4","title":"Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2022-09-01","conditions":"Chronic Kidney Diseases, Bone Diseases, Metabolic","enrollment":100},{"nctId":"NCT05704088","phase":"PHASE4","title":"SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2022-10-08","conditions":"SGLT2 INHIBITORS, Lupus Nephritis, BMD","enrollment":100},{"nctId":"NCT05305911","phase":"PHASE2","title":"Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI","status":"RECRUITING","sponsor":"Minneapolis Heart Institute Foundation","startDate":"2022-08-03","conditions":"Heart Attack, Enlarged Heart","enrollment":81},{"nctId":"NCT05321706","phase":"PHASE3","title":"DAPAgliflozin for Renal Protection in Heart Transplant Recipients","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2022-06-08","conditions":"Heart Transplant Failure, Kidney Failure","enrollment":430},{"nctId":"NCT06373523","phase":"EARLY_PHASE1","title":"MASLD in Primary Hypothyroidism and Efficacy of Dapaglifozin","status":"NOT_YET_RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2024-09-01","conditions":"Hepatic Steato-Fibrosis, Non-Alcoholic Fatty Liver Disease","enrollment":60},{"nctId":"NCT04724837","phase":"PHASE2","title":"Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-04-28","conditions":"Chronic Kidney Disease","enrollment":542},{"nctId":"NCT04004793","phase":"PHASE4","title":"Remission of Type 2 Diabetes With Dapagliflozin (READ Trial)","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-06-12","conditions":"Type 2 Diabetes","enrollment":328},{"nctId":"NCT04707261","phase":"PHASE4","title":"Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)","status":"RECRUITING","sponsor":"Xiangtan Central Hospital","startDate":"2021-08-06","conditions":"Anemia, Heart Failure","enrollment":1990},{"nctId":"NCT03199053","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-10-11","conditions":"Diabetes Mellitus, Type 2","enrollment":256},{"nctId":"NCT03190694","phase":"PHASE2","title":"Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria","status":"COMPLETED","sponsor":"Hiddo Lambers Heerspink","startDate":"2017-11-12","conditions":"Chronic Kidney Diseases, Proteinuria","enrollment":53},{"nctId":"NCT04249778","phase":"PHASE4","title":"Dapagliflozin at Discharge on Hospital Heart Failure Readmission","status":"COMPLETED","sponsor":"Emory University","startDate":"2020-07-29","conditions":"Heart Failure, Diabetes","enrollment":105},{"nctId":"NCT03801642","phase":"PHASE1, PHASE2","title":"Dapagliflozin In Alzheimer's Disease","status":"COMPLETED","sponsor":"Jeff Burns, MD","startDate":"2019-01-29","conditions":"Alzheimer Disease","enrollment":46},{"nctId":"NCT06434025","phase":"PHASE3","title":"IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency","status":"NOT_YET_RECRUITING","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2024-05-24","conditions":"Heart Failure, Systolic, Iron Deficiencies","enrollment":99},{"nctId":"NCT04794517","phase":"PHASE2","title":"Dapagliflozin in Non-diabetic Stage IV CKD","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-11-08","conditions":"Chronic Kidney Diseases","enrollment":32},{"nctId":"NCT05392959","phase":"PHASE4","title":"Effect of the Antidiabetic Drug Dapagliflozin on the Coronary Macrovascular and Microvascular Function in Type 2 Diabetic Patients","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire Saint Pierre","startDate":"2022-06-06","conditions":"Diabetes Mellitus, Type 2","enrollment":4},{"nctId":"NCT06374043","phase":"PHASE4","title":"Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2021-05-11","conditions":"Diabetes Mellitus, Type 2, Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus","enrollment":20},{"nctId":"NCT02981966","phase":"PHASE4","title":"Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2019-05-23","conditions":"Diabetes Mellitus, Type 2","enrollment":32},{"nctId":"NCT02962492","phase":"NA","title":"An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2016-11-01","conditions":"Evaluate Ketogenic Stress","enrollment":70},{"nctId":"NCT03704818","phase":"PHASE1","title":"Dapagliflozin Effects on Hypoglycemia","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2018-10-08","conditions":"Type1 Diabetes Mellitus","enrollment":22},{"nctId":"NCT04333823","phase":"PHASE3","title":"Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial","status":"UNKNOWN","sponsor":"The Hospital for Sick Children","startDate":"2020-12-11","conditions":"Diabetes Mellitus, Type 1","enrollment":100},{"nctId":"NCT05443932","phase":"PHASE4","title":"Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2024-03-04","conditions":"Urolithiasis, Hyperoxaluria","enrollment":32},{"nctId":"NCT04049110","phase":"PHASE3","title":"Dapagliflozin in Physical Exercise in Type 1 Diabetes","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2020-08-25","conditions":"Diabetes Mellitus, Type 1","enrollment":39},{"nctId":"NCT06009874","phase":"NA","title":"Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI","status":"RECRUITING","sponsor":"Mohammad Hussien Tantawy Soliman","startDate":"2023-10","conditions":"Myocardial Infarction","enrollment":80},{"nctId":"NCT05998525","phase":"PHASE3","title":"Dapagliflozin Effects on Coronary Calcium and Epicardial Fat Assessed by Cardiotomography","status":"COMPLETED","sponsor":"Hilda Elizabeth Macías Cervantes","startDate":"2021-06-21","conditions":"Diabete Type 2, Unstable Angina, Myocardial Infarction","enrollment":54},{"nctId":"NCT05993897","phase":"NA","title":"Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling","status":"UNKNOWN","sponsor":"Aswan University","startDate":"2023-08","conditions":"Atrial Fibrillation","enrollment":60},{"nctId":"NCT02981069","phase":"PHASE4","title":"Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2017-12-15","conditions":"Diabetes Mellitus, Type 2","enrollment":90},{"nctId":"NCT04717986","phase":"NA","title":"Dapagliflozin Effects on Mayor Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction (DAPA-AMI)","status":"COMPLETED","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2021-01-26","conditions":"Acute Myocardial Infarction, Cardiovascular Morbidity, Heart Failure","enrollment":188},{"nctId":"NCT04885712","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2021-05-28","conditions":"Type2 Diabetes","enrollment":378},{"nctId":"NCT04258371","phase":"PHASE2","title":"DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2020-02-10","conditions":"Cardiovascular Risk Factor","enrollment":50},{"nctId":"NCT04080518","phase":"PHASE4","title":"Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment","status":"COMPLETED","sponsor":"National Heart Centre Singapore","startDate":"2019-11-11","conditions":"Diabetes Mellitus, Heart Failure","enrollment":40},{"nctId":"NCT05797935","phase":"PHASE4","title":"Evaluation of Changes in Pancreatic Fat Content Using Advanced MR Sequences in Diabetics on Dapagliflozin Therapy","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2021-08-01","conditions":"Pancreatic Lipomatosis","enrollment":50},{"nctId":"NCT05776043","phase":"PHASE3","title":"Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure","status":"UNKNOWN","sponsor":"Medical University of Warsaw","startDate":"2022-03-15","conditions":"Acute Decompensated Heart Failure","enrollment":1364},{"nctId":"NCT02211742","phase":"PHASE4","title":"Dapagliflozin in Type 1 Diabetes","status":"COMPLETED","sponsor":"Medical University Innsbruck","startDate":"2014-08","conditions":"Fasting Glucose, Glucose Excursion, Glycemic Control","enrollment":12},{"nctId":"NCT04035031","phase":"PHASE3","title":"Effects of Dapagliflozin on Hormonal Glucose Homeostasis in Type 1 Diabetes","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2020-01-09","conditions":"Diabetes Mellitus, Type 1","enrollment":13},{"nctId":"NCT03842267","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)","status":"COMPLETED","sponsor":"LG Chem","startDate":"2019-05-13","conditions":"Diabetes Mellitus, Type 2","enrollment":315},{"nctId":"NCT02796170","phase":"PHASE4","title":"Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tulane University School of Medicine","startDate":"2016-03","conditions":"Type 2 Diabetes, Hypertension","enrollment":11},{"nctId":"NCT03030235","phase":"PHASE4","title":"Dapagliflozin in PRESERVED Ejection Fraction Heart Failure","status":"COMPLETED","sponsor":"Saint Luke's Health System","startDate":"2017-03-01","conditions":"Chronic Heart Failure With Preserved Systolic Function","enrollment":324},{"nctId":"NCT05550441","phase":"PHASE4","title":"Effect of Dapagliflozin on VT in Patients With Heart Failure.","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-11-15","conditions":"Heart Failure","enrollment":120},{"nctId":"NCT05226897","phase":"PHASE3","title":"Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients","status":"UNKNOWN","sponsor":"Yooyoung Pharmaceutical Co., Ltd.","startDate":"2021-07-12","conditions":"Type 2 Diabetes","enrollment":256},{"nctId":"NCT03608358","phase":"PHASE3","title":"Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2019-02-27","conditions":"Type 2 Diabetes Mellitus","enrollment":41}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo for dapagliflozin","genericName":"Placebo for dapagliflozin","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Used as control comparator in clinical trials for dapagliflozin efficacy evaluation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}